Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer

Tomonari Sasaki, Katsumasa Nakamura, Yoshiyuki Shioyama, Ohga Saiji, Takashi Toba, Yusuke Urashima, Tadamasa Yoshitake, Hiromi Terashima, Hirofumi Koga, Seiji Naito, Hideya Noma, Kiyoshi Komatsu, Akito Yamaguchi, Yoshiharu Hiratsuka, Tomomi Hirano, Kiyohiko Hanada, Madoka Abe, Yasuhito Fujisawa, Hiroshi Honda

研究成果: ジャーナルへの寄稿記事

6 引用 (Scopus)

抄録

Background: The optimal role of postoperative radiotherapy for patients with prostate cancer remains undefined. Materials and Methods: The medical records of 70 patients (median age: 66 years), who had received radical radiotherapy (RT) between the years 1996 and 2004 after radical prostatectomy (RP), were analyzed. Fifteen patients had received immediate adjuvant RT, while the other 55 patients had received salvage therapy. Hormonal therapy had been performed in 28 patients before RT and continued in two of them concurrently with RT. A median dose of 60 Gy was delivered to the prostate bed. Pelvic node irradiation was performed in all patients. Results: After a median follow-up period of 23 months, 21 patients had experienced biochemical failure. Actuarial 3- and 5-year biochemical relapse-free survival estimates were 67.4%. No patient had local failure, although distant metastases with biochemical failure were found in five patients. On univariate analysis, the following were significant for biochemical failures: seminar vesicle involvement, serum PSA level >1 ng/ml before RT, pathological pelvic node involvement, RT indication (adjuvant vs. salvage) and Gleason score. However, only the serum PSA level before RT was significant on multivariate analysis. Conclusion: Postoperative RT with a pre-RT PSA level <0.1 ng/ml seemed to be effective in patients with prostate cancer.

元の言語英語
ページ(範囲)2367-2374
ページ数8
ジャーナルAnticancer research
26
発行部数3 B
出版物ステータス出版済み - 5 1 2006

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Radiotherapy
Therapeutics
Adjuvant Radiotherapy
Salvage Therapy
Neoplasm Grading
Prostatectomy
Serum
Medical Records
Prostate
Multivariate Analysis
Neoplasm Metastasis
Recurrence
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer. / Sasaki, Tomonari; Nakamura, Katsumasa; Shioyama, Yoshiyuki; Saiji, Ohga; Toba, Takashi; Urashima, Yusuke; Yoshitake, Tadamasa; Terashima, Hiromi; Koga, Hirofumi; Naito, Seiji; Noma, Hideya; Komatsu, Kiyoshi; Yamaguchi, Akito; Hiratsuka, Yoshiharu; Hirano, Tomomi; Hanada, Kiyohiko; Abe, Madoka; Fujisawa, Yasuhito; Honda, Hiroshi.

:: Anticancer research, 巻 26, 番号 3 B, 01.05.2006, p. 2367-2374.

研究成果: ジャーナルへの寄稿記事

Sasaki, T, Nakamura, K, Shioyama, Y, Saiji, O, Toba, T, Urashima, Y, Yoshitake, T, Terashima, H, Koga, H, Naito, S, Noma, H, Komatsu, K, Yamaguchi, A, Hiratsuka, Y, Hirano, T, Hanada, K, Abe, M, Fujisawa, Y & Honda, H 2006, 'Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer', Anticancer research, 巻. 26, 番号 3 B, pp. 2367-2374.
Sasaki, Tomonari ; Nakamura, Katsumasa ; Shioyama, Yoshiyuki ; Saiji, Ohga ; Toba, Takashi ; Urashima, Yusuke ; Yoshitake, Tadamasa ; Terashima, Hiromi ; Koga, Hirofumi ; Naito, Seiji ; Noma, Hideya ; Komatsu, Kiyoshi ; Yamaguchi, Akito ; Hiratsuka, Yoshiharu ; Hirano, Tomomi ; Hanada, Kiyohiko ; Abe, Madoka ; Fujisawa, Yasuhito ; Honda, Hiroshi. / Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer. :: Anticancer research. 2006 ; 巻 26, 番号 3 B. pp. 2367-2374.
@article{8acc39b8820c4e0ab30eb467a2699763,
title = "Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer",
abstract = "Background: The optimal role of postoperative radiotherapy for patients with prostate cancer remains undefined. Materials and Methods: The medical records of 70 patients (median age: 66 years), who had received radical radiotherapy (RT) between the years 1996 and 2004 after radical prostatectomy (RP), were analyzed. Fifteen patients had received immediate adjuvant RT, while the other 55 patients had received salvage therapy. Hormonal therapy had been performed in 28 patients before RT and continued in two of them concurrently with RT. A median dose of 60 Gy was delivered to the prostate bed. Pelvic node irradiation was performed in all patients. Results: After a median follow-up period of 23 months, 21 patients had experienced biochemical failure. Actuarial 3- and 5-year biochemical relapse-free survival estimates were 67.4{\%}. No patient had local failure, although distant metastases with biochemical failure were found in five patients. On univariate analysis, the following were significant for biochemical failures: seminar vesicle involvement, serum PSA level >1 ng/ml before RT, pathological pelvic node involvement, RT indication (adjuvant vs. salvage) and Gleason score. However, only the serum PSA level before RT was significant on multivariate analysis. Conclusion: Postoperative RT with a pre-RT PSA level <0.1 ng/ml seemed to be effective in patients with prostate cancer.",
author = "Tomonari Sasaki and Katsumasa Nakamura and Yoshiyuki Shioyama and Ohga Saiji and Takashi Toba and Yusuke Urashima and Tadamasa Yoshitake and Hiromi Terashima and Hirofumi Koga and Seiji Naito and Hideya Noma and Kiyoshi Komatsu and Akito Yamaguchi and Yoshiharu Hiratsuka and Tomomi Hirano and Kiyohiko Hanada and Madoka Abe and Yasuhito Fujisawa and Hiroshi Honda",
year = "2006",
month = "5",
day = "1",
language = "English",
volume = "26",
pages = "2367--2374",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 B",

}

TY - JOUR

T1 - Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer

AU - Sasaki, Tomonari

AU - Nakamura, Katsumasa

AU - Shioyama, Yoshiyuki

AU - Saiji, Ohga

AU - Toba, Takashi

AU - Urashima, Yusuke

AU - Yoshitake, Tadamasa

AU - Terashima, Hiromi

AU - Koga, Hirofumi

AU - Naito, Seiji

AU - Noma, Hideya

AU - Komatsu, Kiyoshi

AU - Yamaguchi, Akito

AU - Hiratsuka, Yoshiharu

AU - Hirano, Tomomi

AU - Hanada, Kiyohiko

AU - Abe, Madoka

AU - Fujisawa, Yasuhito

AU - Honda, Hiroshi

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Background: The optimal role of postoperative radiotherapy for patients with prostate cancer remains undefined. Materials and Methods: The medical records of 70 patients (median age: 66 years), who had received radical radiotherapy (RT) between the years 1996 and 2004 after radical prostatectomy (RP), were analyzed. Fifteen patients had received immediate adjuvant RT, while the other 55 patients had received salvage therapy. Hormonal therapy had been performed in 28 patients before RT and continued in two of them concurrently with RT. A median dose of 60 Gy was delivered to the prostate bed. Pelvic node irradiation was performed in all patients. Results: After a median follow-up period of 23 months, 21 patients had experienced biochemical failure. Actuarial 3- and 5-year biochemical relapse-free survival estimates were 67.4%. No patient had local failure, although distant metastases with biochemical failure were found in five patients. On univariate analysis, the following were significant for biochemical failures: seminar vesicle involvement, serum PSA level >1 ng/ml before RT, pathological pelvic node involvement, RT indication (adjuvant vs. salvage) and Gleason score. However, only the serum PSA level before RT was significant on multivariate analysis. Conclusion: Postoperative RT with a pre-RT PSA level <0.1 ng/ml seemed to be effective in patients with prostate cancer.

AB - Background: The optimal role of postoperative radiotherapy for patients with prostate cancer remains undefined. Materials and Methods: The medical records of 70 patients (median age: 66 years), who had received radical radiotherapy (RT) between the years 1996 and 2004 after radical prostatectomy (RP), were analyzed. Fifteen patients had received immediate adjuvant RT, while the other 55 patients had received salvage therapy. Hormonal therapy had been performed in 28 patients before RT and continued in two of them concurrently with RT. A median dose of 60 Gy was delivered to the prostate bed. Pelvic node irradiation was performed in all patients. Results: After a median follow-up period of 23 months, 21 patients had experienced biochemical failure. Actuarial 3- and 5-year biochemical relapse-free survival estimates were 67.4%. No patient had local failure, although distant metastases with biochemical failure were found in five patients. On univariate analysis, the following were significant for biochemical failures: seminar vesicle involvement, serum PSA level >1 ng/ml before RT, pathological pelvic node involvement, RT indication (adjuvant vs. salvage) and Gleason score. However, only the serum PSA level before RT was significant on multivariate analysis. Conclusion: Postoperative RT with a pre-RT PSA level <0.1 ng/ml seemed to be effective in patients with prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=33745561070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745561070&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 2367

EP - 2374

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 B

ER -